Ibrutinib may inhibit the macrophage-mediate response to Mycobacterium tuberculosis (Mtb) among patients with chronic lymphocytic leukemia (CLL), according to an abstract presented at the XVII International Workshop on Chronic Lymphocytic Leukemia (iwCLL).1
